Drug intelligence / Profile preview

lactitol monohydrate + ispaghula husk

Development stage: Unknown
Lead developer: Minerve Remedies
Modality: Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

lactitol monohydrate + ispaghula husk is an oral combination pharmaceutical product marketed by MINERVE for constipation and related gastrointestinal disorders. The combination pairs **lactitol**, a non-absorbable osmotic laxative that increases colonic water content after fermentation and osmotic activity in the gut lumen, with **ispaghula husk**, a bulk-forming soluble fiber that absorbs water, increases stool bulk, and facilitates bowel transit. Together, the agents are intended to soften stool, improve stool frequency, and reduce straining in patients with constipation.

Other names: lactitol monohydrate + ispaghula husklactitol + psyllium husklactitol + ispaghula husk

Beyond the preview

Go deeper on lactitol monohydrate + ispaghula husk.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactitol monohydrate + ispaghula husk.

Explore the full profile